Novartis

Photo
11.02.2025 • News

Novartis to Acquire Anthos Therapeutics

Swiss drugmaker Novartis has agreed to acquire Anthos Therapeutics, a Boston, US-based biopharmaceutical company with its lead compound abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Photo
22.11.2024 • News

Novartis Acquires Kate Therapeutics for $1.1 Billion

Swiss pharmaceutical giant Novartis has acquired Kate Therapeutics for $1.1 billion. The San Diego, US-headquartered preclinical stage biotechnology company develops adeno-associated virus (AAV)-based gene therapies to treat inherited neuromuscular diseases.

Photo
23.08.2024 • News

Novartis and Versant Launch Borealis Biosciences

Novartis announced it has partnered with Versant Ventures to form Borealis Biosciences, an independent, discovery-stage biotechnology company based in Vancouver, Canada, focused on developing next-generation xRNA-based medicines for kidney diseases.

Photo
26.07.2024 • News

Dren Bio, Novartis to Develop Bispecific Cancer Antibodies

US biopharmaceutical company Dren Bio, a developer of novel antibody therapeutics, has entered into a collaboration with Novartis Pharma, a subsidiary of Novartis. The collaboration will focus on the discovery and development of therapeutic bispecific antibodies for cancer using Dren Bio’s proprietary targeted myeloid engager and phagocytosis platform.

Photo
03.05.2024 • News

Novartis to Acquire Mariana Oncology

Swiss drugmaker Novartis agreed to acquire Mariana Oncology, a US biotechnology company based in Watertown, Massachusetts, that develops novel radioligand therapies (RLTs) for the treatment of cancer.

Photo
20.03.2024 • NewsChemistry

Integrated Continuous Manufacturing in Pharmaceuticals

An innovative manufacturing platform called integrated continuous manufacturing (ICM) represents a completely modernized model for drug manufacturing. In contrast to batch processes, ICM’s unique operational advantages will allow for cost-competitive end-to-end manufacturing and enable a more robust and responsive supply chain for critical drugs.

Photo
10.01.2024 • News

Isomorphic Labs to Collaborate with Eli Lilly and Novartis

Isomorphic Labs announced strategic collaborations with leading pharmaceutical companies, Eli Lilly and Company and Novartis. These partnerships have the potential to be worth nearly €2.75 billion ($3 billion) to Isomorphic Labs, excluding any royalties that may result from future drug sales. Both collaborations are multi-target, focused on small molecules, and include a combination of upfront and milestone payments.

Photo
12.05.2023 • News

Sandoz in Biosimilars Pact with Just – Evotec Biologics

As Novartis moves toward shedding generics subsidiary Sandoz, which it touts as a global leader in off-patent generic and biosimilar drugs, Sandoz has agreed a multi-year strategic partnership with Just –Evotec Biologics, the Seattle, Washington-based US subsidiary of Germany’s Evotec, to develop and manufacture biosimilars.

Photo
22.03.2023 • News

Sangamo Reviews Options as Drugmakers Terminate Deals

US biotech Sangamo Therapeutics is studying alternative options to advance its neurological disease programs after both Novartis and Biogen ended their respective collaborations. The California-based company said options could include potentially developing the programs internally, or with another partner.

Photo
17.03.2023 • News

Sandoz Builds Biologics Plant in Slovenia

Sandoz, the generics and biosimilars arm of Swiss drugmaker Novartis, has signed a Memorandum of Understanding to build a biologics production plant in Lendava, Slovenia.

Photo
31.01.2023 • News

EMA Reviewing Approval of Novartis’ Adakveo

The European Medicines Agency (EMA) said its Committee for Medicinal Products for Human Use (CHMP) has begun reviewing its marketing authorization for Novartis’ Adakveo, a medicine to prevent vaso-occlusive pain crises in patients with sickle cell disease.

Photo
05.01.2023 • News

Novartis to Pay $245 Million in ’Pay for Delay’ Settlement

Novartis has agreed to pay a total of $245 million to settle lawsuits filed by direct purchasers, indirect purchasers and retailers accusing it of colluding with Par Pharmaceutical to delay the launch of a generic version of its Exforge (valsartan/amlodipine) hypertension drug.

Photo
22.12.2022 • News

Jobs to Go at Novartis US Headquarters

As part of plans, announced in dribbles, to carve 8,000 jobs out of its global workforce to save $1 billion, Swiss drugs giant Novartis is eliminating 285 staff positions across its headquarters sites in the US state of New Jersey.

Photo
15.11.2022 • News

BioNTech Buys Novartis Singapore Plant for Asia HQ

German Covid-19 vaccine specialist BioNTech has acquired a production facility in Singapore from Swiss drugmaker Novartis that will serve as a manufacturing base in addition to being its Asia-Pacific headquarters.

Photo
09.11.2022 • News

Sandoz Invests in Extra European Antibiotic Capacity

Sandoz, the generics arm of Swiss drugmaker Novartis, has announced plans to spend an additional €50 million on raising European manufacturing capacity for finished dosage forms of amoxicillin and other key penicillin products.

Photo
18.10.2022 • TopicsTechnology

AI Maturity Model for GxP Application

Artificial intelligence (AI) has become one of the supporting pillars for digitalization in many areas of the business world. The pharmaceutical industry and its GxP-regulated areas also want to use AI in a beneficial way, but only a small fraction of companies follows a systematic approach for the digitalization of their operations and validation. However, the assurance of integrity and quality of outputs via computerized system validation is essential for applications in GxP environments.

Photo
09.09.2022 • News

Novartis to Shutter a Sandoz US Plant

In advance of the planned spinoff of generics subsidiary Sandoz into a standalone generics producer, Novartis has announced it is closing one of the subsidiary’s US plants.

Photo
06.09.2022 • News

Novartis Sued over its own Drug

Swiss drugmaker Novartis, already embroiled in a number of lawsuits against generics producers seeking to create copies of its blockbuster cardiac insufficiency treatment Entresto, is now itself being sued.

Photo
13.06.2022 • News

Samsung Biologics in $81 Million Deal with Novartis

In the their first-ever collaboration, South Korea’s Samsung Biologics and Switzerland’s Novartis have inked an initial $81 million contract manufacturing and development deal, Samsung said in a regulatory filing.

Photo
19.04.2022 • News

Sandoz Launches Generic Combigan Drops

Novartis subsidiary Sandoz has launched a generic version of Combigan, the ocular hypertensiondrug made by AbbVie’s Allergan arm. The copy of the off-patent eye drops will be marketed only in the US, where Allergan racked up sales of $373 million with the original product in 2021.

Photo
05.04.2022 • News

Novartis Creates new Innovative Medicines Unit

Swiss pharma powerhouse Novartis is merging its pharmaceuticals and oncology businesses into a new unit called Innovative Medicines (IM). The restructuring that will create separate US and International commercial organizations is expected to increase focus, strengthen competitiveness and drive synergies in high-value medicines.

Photo
22.02.2022 • News

Novartis Takes Gyroscope Therapeutics for $1.5 Billion

Swiss pharma Novartis has acquired Gyroscope Therapeutics, a clinical-stage gene therapy company focused on diseases of the eye, from Syncona, a UK-based firm that says it focuses on founding and building businesses with exceptional science in areas of high unmet medical need.

Photo
02.02.2022 • News

Private Equity Buyers Seen as Circling Sandoz

US private equity firms Blackstone and Carlyle may make a joint offer for the Novartis generics unit Sandoz, Bloomberg reports. With six other possible bidders seen as circling Basel-based Sandoz, the news agency’s sources said this sale could shape up to be one of the biggest-ever buyout deals, valued at around $25 billion.

Photo
14.12.2021 • News

Novartis May Have Sandoz Buyer on the Hook

Novartis and market watchers alike have been dropping repeated hits that a sale of the Swiss drugs giant’s Sandoz-branded generic drugs arm may be closer than has been hinted up to now. In an interview with German weekly news magazine Wirtschaftswoche last week, CEO Vas Narasimhan said, however, that beyond several requests for information no concrete offers are currently on the table.

Photo
08.11.2021 • News

Novartis Selling Roche Shares Back to Swiss Rival

In the reverse of a deal sealed 20 years ago, Novartis is selling the 33% stake it bought in Roche back to the compatriot drugmaker. The latest transaction between the two Swiss giants sees 53.3 million shares moving across Basel again for a much higher price of $20.7 billion.

Photo
15.09.2021 • News

The Transition to Digitalization in the Pharmaceutical Industry

ISPE and its members are developing the roadmap to introduce Industry 4.0, also called the Smart Factory, at the pharmaceutical industry as Pharma 4.0 – an operating model that is interconnected, meaning that the digital tools allow for a fully connected network to enable direct communication between all levels in an organization.

Photo
06.09.2021 • News

Expert Statement: Markus Zeitz, Novartis

ISPE and its members are developing the roadmap to introduce Industry 4.0, also called the Smart Factory, at the pharmaceutical industry as Pharma 4.0 – an operating model that is interconnected, meaning that the digital tools allow for a fully connected network to enable direct communication between all levels in an organization.

Photo
11.05.2021 • News

BASF Invests in Enzymes in Austria

BASF is investing in its enzymes business at the Novartis Kundl/Schaftenau Campus in Austria. The German chemical giant said the agreement with the Swiss group – for which financial details were not disclosed – will enable it to develop a world-scale operation for bacterial enzymes and biotechnology products.

Photo
05.03.2021 • News

Novartis to Help CureVac Speed Vaccine Rollout

A few weeks ago, Novartis said it was exploring ways to participate in the European Covid-19 vaccine manufacturing effort. In the meantime, it has been busy. On Mar. 4 the Swiss drugmaker signed an initial manufacturing agreement with CureVac to boost the German biotech’s overall vaccine capacity by 50 million doses in 2021 and 200 million doses in 2022.

261 more articles

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.